<DOC>
	<DOCNO>NCT00833248</DOCNO>
	<brief_summary>The purpose phase 3B trial see well new trial drug ( degarelix ) work term reduce size prostate volume prostate cancer patient schedule undergo subsequent radiotherapy treatment prostate cancer . Prior receive radiotherapy , recommend patient intermediate high risk prostate cancer pre-treated hormone therapy ( so-called neoadjuvant therapy ) know reduce size prostate thereby decrease require radiation field enable safe effective treatment . In trial , participant randomly select ( like flip coin ) receive either degarelix give alone standard hormone therapy ( combination goserelin bicalutamide . The treatment give three month prostate size measure ultra sound begin end trial . The participant require come clinic 5 6 visit three month .</brief_summary>
	<brief_title>Neoadjuvant Study Investigating Degarelix Patients Suffering From Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patient give write informed consent trialrelated activity perform . Has confirm prostate cancer type treatment need . Previous treatment prostate cancer Previous transurethral resection prostate Patients lymph node positive metastatic disease Use urethral catheter Current treatment 5alpha reductase inhibitor Î±adrenoceptor antagonist . History severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema . Hypersensitivity towards component investigational product Other previous cancer within last five year exception prostate cancer type skin cancer . Certain risk factor abnormal heart rhythms/QT prolongation ( correct QT interval 450 msec. , Torsades de Pointes use certain medication potential risk ) Clinical disorder prostate cancer include limited renal , haematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease , alcohol drug abuse conditionals judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>